Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis

Abstract

Declaration of financial/other relationships  WP has served as a paid advisor to Molnlycke Health Care and is a Principal at Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. This arrangement has been reviewed and approved by University of Southern California in accordance with its conflict of interest policies.  SM is an employee of Monument Analytics.  NR is an employee of Monument Analytics.  BC is an employee of Monument Analytics  FC is an employee of Monument Analytics  JB has received consulting fees from Monument Analytics, a healthcare consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.  JT is an employee and co-founding Principal at Monument Analytics. GCA is past Chair and a current member of FDA's Peripheral and Central Nervous System Advisory Committee; is a co-founding Principal and equity holder in Monument Analytics, a healthcare consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a past member of OptumRx's National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.

Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations

“… 6 Nevertheless, going forward, healthcare systems will need to pay closer attention to the cost effectiveness of interventions for COVID-19. Although some public health measures, such as screening and vaccination programs, have been the subject of economic evaluations, 7 , 8 , 9 , 10 , 11 , 12 , 13 HTA agencies are typically most interested in the value of diagnostic and therapeutic interventions. Evidence from previous pandemics with similar characteristics suggests antiviral treatments may represent a cost-effective use of resources, 14 but assessments specific to COVID-19 are needed.…”

COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?

“…Studies have shown that besides being effective in terms of clinical outcome, COVID-19 vaccines are also able to reduce health care costs by 80% or more ( 19 ). This is in line with our findings, according to which the expenditure for ordinary hospitalizations and ICU admissions of unvaccinated individuals account for 48% of the total expenditure for all hospitalizations.…”

Cost Utility of Vaccination Against COVID-19 in Brazil

“…The mean utility of asymptomatic patients was considered to be equal to that of the general Brazilian population (0.88), progressively decreasing in patients with mild symptoms (0.833), hospitalized in the ward (0.5), hospitalized in the ICU (0.05), and dead (0.0). 24 , 25 …”